Entinostat (MS-275)

For research use only. Not for use in humans.

Catalog No.S1053 Synonyms: SNDX-275

271 publications

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Entinostat (MS-275) has been cited by 271 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnntTWM2OD1yLkC2NUDPxE1? NGf1dGdUSU6JRWK=
ALL-PO NIDFNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnsTWM2OD1yLkC2N|U2KM7:TR?= MkDoV2FPT0WU
697 NFn1[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;kfWlEPTB;MD6wPVk4PiEQvF2= M2nNT3NCVkeHUh?=
NCI-H748 Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMUCzN|Qh|ryP M2SxZ3NCVkeHUh?=
NKM-1 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMUC5NVIh|ryP MnKzV2FPT0WU
ES1 NIXNNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMUGyOVUh|ryP NWj5ZmZJW0GQR1XS
NCI-H1963 NF;PS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMUG1O|kh|ryP MVfTRW5ITVJ?
NCI-H1417 M{KxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjlephKSzVyPUCuNVI6PzRizszN MmThV2FPT0WU
NEC8 M1PpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPMdYJKSzVyPUCuNVM2OjdizszN NX\nZppsW0GQR1XS
CRO-AP2 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlizTWM2OD1yLkG2PFg6KM7:TR?= M1vkNXNCVkeHUh?=
A3-KAW M3;scGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r5VmlEPTB;MD6xO|YzPyEQvF2= NE\TR4hUSU6JRWK=
SF539 NUnycoV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHqTWM2OD1yLkG5OVk{KM7:TR?= NFjKR25USU6JRWK=
NOS-1 M3:2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;Jb4lKSzVyPUCuNVk3OTlizszN M1TTVnNCVkeHUh?=
NTERA-S-cl-D1 NHnzUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rzUWlEPTB;MD6yNFEyOyEQvF2= MWrTRW5ITVJ?
COR-L88 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nab2lEPTB;MD6yNlk2QSEQvF2= NXfh[5RIW0GQR1XS
EM-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMkSwO|kh|ryP MVPTRW5ITVJ?
KARPAS-45 Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjnRVhKSzVyPUCuNlc5OzNizszN NWjvN4ZzW0GQR1XS
DSH1 NX;MWVdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC5TWM2OD1yLkK4O|A5KM7:TR?= MlPYV2FPT0WU
HT-144 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwM{CyOVYh|ryP NYLU[HBbW0GQR1XS
ATN-1 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fpZ2lEPTB;MD6zNFU4PiEQvF2= MnfHV2FPT0WU
HEL NV\CZmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwM{GzOFgh|ryP MX;TRW5ITVJ?
NB12 M3zFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rkSmlEPTB;MD6zNVc2PiEQvF2= MoXRV2FPT0WU
LU-139 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XFTWlEPTB;MD6zN|UyKM7:TR?= M3njPXNCVkeHUh?=
J-RT3-T3-5 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFW2cm9KSzVyPUCuN|M4OTZizszN MUTTRW5ITVJ?
MOLT-13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHvTWM2OD1yLkOzPFEh|ryP M{fTU3NCVkeHUh?=
SR NGj0UmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnaO3ZKSzVyPUCuN|QzPjFizszN MnywV2FPT0WU
CMK MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LSWGlEPTB;MD6zOVczPyEQvF2= MnXOV2FPT0WU
ES8 NXW2fWRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr3U41KSzVyPUCuN|YxOjJizszN MnnkV2FPT0WU
LB647-SCLC NXLOOVE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIewPGFKSzVyPUCuN|Y4OyEQvF2= MWfTRW5ITVJ?
TE-8 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPvTHFKSzVyPUCuN|Y6OzVizszN MX7TRW5ITVJ?
BV-173 NFrVfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnCTWM2OD1yLkO3NVIyKM7:TR?= MmT2V2FPT0WU
DEL MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwM{e0PFch|ryP M3r1RXNCVkeHUh?=
ARH-77 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHxTWM2OD1yLkO4NVk{KM7:TR?= M1rYbHNCVkeHUh?=
NCCIT MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\nfmlEPTB;MD6zPFY1QSEQvF2= MojNV2FPT0WU
RPMI-8402 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwM{i3NFEh|ryP NEPoTItUSU6JRWK=
MONO-MAC-6 NF7DSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvITWM2OD1yLkO4O|c3KM7:TR?= MVjTRW5ITVJ?
SK-MM-2 M1;EbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PD[GlEPTB;MD6zPVg3QCEQvF2= NHXPWGZUSU6JRWK=
CHP-126 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3SwXWlEPTB;MD60NFI{OSEQvF2= M37NXXNCVkeHUh?=
A101D M3PnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwNECzJO69VQ>? NHjycWRUSU6JRWK=
SCH NXLWZYJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz3S3RKUUN3ME2wMlQxOzR{IN88US=> M17uNnNCVkeHUh?=
NMC-G1 NHHaVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjSVphKSzVyPUCuOFA{PjdizszN MUTTRW5ITVJ?
NCI-H209 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwNEC2NVMh|ryP NWPOPGVOW0GQR1XS
MOLT-16 NHy4SZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwNEGwNVch|ryP MXLTRW5ITVJ?
RPMI-6666 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXiSnBuUUN3ME2wMlQyOTJizszN NVTp[3hjW0GQR1XS
OPM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL2[I1JUUN3ME2wMlQyPTF|IN88US=> MorMV2FPT0WU
MRK-nu-1 NV3zcpQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXvcoZKSzVyPUCuOFMyPTNizszN NUPzTFdoW0GQR1XS
BC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwNEO0NFMh|ryP M37aWXNCVkeHUh?=
MHH-NB-11 NEi0bW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PQOWlEPTB;MD60N|Q2OyEQvF2= MkjpV2FPT0WU
Ramos-2G6-4C10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nSb2lEPTB;MD60N|g6PyEQvF2= NF;PVWFUSU6JRWK=
LS-513 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwNES1NFEh|ryP NGLTOYFUSU6JRWK=
K5 NYrtcm1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwNEewNlUh|ryP NIfwcoNUSU6JRWK=
HOP-62 NWfDe496T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPvUlJIUUN3ME2wMlQ5OzV6IN88US=> MkfyV2FPT0WU
NCI-H187 M{SyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnftTWM2OD1yLkS5NlI4KM7:TR?= MoK2V2FPT0WU
BE-13 M3W0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwNEm2OlEh|ryP NXfU[YhHW0GQR1XS
HC-1 M3rZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTrZohMUUN3ME2wMlUxPDd|IN88US=> MYnTRW5ITVJ?
ACN M331XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonrTWM2OD1yLkWxNFI5KM7:TR?= MVrTRW5ITVJ?
HCC1599 NX7FN4FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH2wcndKSzVyPUCuOVE2PyEQvF2= NIC4O2xUSU6JRWK=
MV-4-11 M4\nW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHkOWpKSzVyPUCuOVMxPDFizszN MUfTRW5ITVJ?
LC-2-ad M4fldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXuTWM2OD1yLkWzOlY{KM7:TR?= NHzSdVRUSU6JRWK=
HL-60 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwNUSyOlEh|ryP Mn[zV2FPT0WU
NB17 M3jvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLzZ5FRUUN3ME2wMlU1OzhizszN NUPLRmpLW0GQR1XS
TE-1 NITCcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PEfmlEPTB;MD61OVMxPiEQvF2= MlyyV2FPT0WU
NCI-H524 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fHNWlEPTB;MD61OVQxOSEQvF2= MnOzV2FPT0WU
MZ7-mel NEL0NmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzyemU2UUN3ME2wMlU3OTB3IN88US=> MX3TRW5ITVJ?
L-363 M4X2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwNU[2OVch|ryP MlexV2FPT0WU
BL-41 M3PMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwNU[4PFkh|ryP M1j3cnNCVkeHUh?=
LU-134-A MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrtdYNuUUN3ME2wMlU4ODd|IN88US=> NX3pRmFRW0GQR1XS
SIG-M5 NV\UbGt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLxSZJKSzVyPUCuOVc5PDhizszN NH30VphUSU6JRWK=
ONS-76 Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL1TWM2OD1yLkW4NlQzKM7:TR?= MkSyV2FPT0WU
KARPAS-299 MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwNUi1NFQh|ryP MWPTRW5ITVJ?
DU-4475 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjjOoRKSzVyPUCuOVg4ODNizszN MYHTRW5ITVJ?
NB69 NGj0bJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwNUm4NlUh|ryP NYT0VlRxW0GQR1XS
MHH-PREB-1 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLBTWM2OD1yLk[wO|E6KM7:TR?= NFf5T21USU6JRWK=
LU-165 NFfrOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwNkG4NVIh|ryP M{jqcnNCVkeHUh?=
LOUCY NWC3O2dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwNkOzOlQh|ryP NYjrOoFrW0GQR1XS
NCI-H526 M4D4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG0TWM2OD1yLk[zOVQyKM7:TR?= NUj1OXJzW0GQR1XS
KE-37 Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwNkSyO|Yh|ryP M{jm[HNCVkeHUh?=
NALM-6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwNkS4OkDPxE1? Mn\UV2FPT0WU
CW-2 NF\CVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon5TWM2OD1yLk[1O|k1KM7:TR?= MmTEV2FPT0WU
SU-DHL-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn6zTWM2OD1yLk[1PVQ4KM7:TR?= MUnTRW5ITVJ?
NB13 NGrocm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonJTWM2OD1yLk[2PFE4KM7:TR?= NHjme4ZUSU6JRWK=
QIMR-WIL MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITLTpdKSzVyPUCuOlg{PDNizszN M4q1VnNCVkeHUh?=
ECC12 M2jSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwN{CwPFYh|ryP MojHV2FPT0WU
KALS-1 M1zBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOzellKSzVyPUCuO|A1QTJizszN NE\2Wm1USU6JRWK=
COR-L279 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwN{C5PVYh|ryP M33WZXNCVkeHUh?=
NB14 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr5TWM2OD1yLkeyOlE4KM7:TR?= M3TDTXNCVkeHUh?=
CCRF-CEM NH;PS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfsNnZKSzVyPUCuO|Q3PjFizszN NF\WV49USU6JRWK=
SW954 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj0OGJiUUN3ME2wMlc2QTl7IN88US=> NGHSeIJUSU6JRWK=
IST-SL1 MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXBTWM2OD1yLke3N|Q5KM7:TR?= MU\TRW5ITVJ?
LAMA-84 NVzVZYZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\teWlEPTB;MD63O|U3PyEQvF2= MmHxV2FPT0WU
Daudi NHrTVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPxe4dKSzVyPUCuO|c3QDFizszN NU\wXJVbW0GQR1XS
BC-3 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XwOWlEPTB;MD63PFMxQCEQvF2= MXTTRW5ITVJ?
HCC2998 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC2WIh2UUN3ME2wMlc5OzZizszN NVHjR217W0GQR1XS
NCI-H69 M{Tn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGWySG1KSzVyPUCuPFAyPDdizszN M333XnNCVkeHUh?=
CPC-N MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwOEC1NlQh|ryP M1Hae3NCVkeHUh?=
NOMO-1 NWDyRVh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\YTWM2OD1yLkixNFg1KM7:TR?= NWHlU4J1W0GQR1XS
CESS MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f5b2lEPTB;MD64NVE6PyEQvF2= M1PtR3NCVkeHUh?=
LC4-1 Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPVUphKSzVyPUCuPFQxODdizszN Ml\hV2FPT0WU
BL-70 NUjC[lFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\LXJlqUUN3ME2wMlg2PzB{IN88US=> MkPwV2FPT0WU
ES4 NGTI[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwOEW4Olgh|ryP M4PTWXNCVkeHUh?=
HCE-T M4LufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwOEexO|Eh|ryP NI\JN2NUSU6JRWK=
JAR NGXLW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDUTWM2OD1yLki3PFI4KM7:TR?= NUDsTIhUW0GQR1XS
ST486 NWXoUJJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GweGlEPTB;MD64O|kyPyEQvF2= MmTEV2FPT0WU
KS-1 NYS2[oRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXjdJJKSzVyPUCuPFgxQTZizszN NHK3dFBUSU6JRWK=
GDM-1 NU\FcVJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjVNHRUUUN3ME2wMlg5Pjh5IN88US=> MoK0V2FPT0WU
EHEB NXPDSWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1eyWGlEPTB;MD65NlU5PSEQvF2= MXHTRW5ITVJ?
LB2518-MEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmxTWM2OD1yLkmzNlg1KM7:TR?= Mkn5V2FPT0WU
GOTO M{HrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwOUWwO|Yh|ryP NGqwdGRUSU6JRWK=
LXF-289 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwOUW5NFEh|ryP NYnjSoN6W0GQR1XS
ES6 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3KxV2lEPTB;MD65OlQ{PyEQvF2= MU\TRW5ITVJ?
OS-RC-2 M{XoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rNWGlEPTB;MD65Olg{KM7:TR?= NWDpbmlSW0GQR1XS
DMS-153 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzyTWM2OD1yLkm3OFY6KM7:TR?= MY\TRW5ITVJ?
SK-PN-DW NEjRN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnCOYZDUUN3ME2wMlk4QDNzIN88US=> NHm4UFBUSU6JRWK=
HH MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LsNWlEPTB;MD65PFk2QSEQvF2= NW\JepIyW0GQR1XS
SH-4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn76TWM2OD1zLkCyOFEh|ryP M4XJVnNCVkeHUh?=
MOLT-4 NXnBVYsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XmN2lEPTB;MT6wN|Q2PCEQvF2= MWfTRW5ITVJ?
TGW NVX1dmFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwMEe2O|Uh|ryP NGr5U2xUSU6JRWK=
L-540 NF\PU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7IOVNKSzVyPUGuNVA3ODRizszN MorFV2FPT0WU
PF-382 NEnxblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFwMUG1NVMh|ryP MYPTRW5ITVJ?
LC-1F NUHhbIR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O3RWlEPTB;MT6xNlAxPyEQvF2= MoWxV2FPT0WU
OVCAR-4 NELNb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOyS|I{UUN3ME2xMlE{OTZ3IN88US=> NYLTV4xNW0GQR1XS
A4-Fuk Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwMUWzOlQh|ryP MWrTRW5ITVJ?
HCC2218 M2Pxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PHN2lEPTB;MT6xOlY1OSEQvF2= NV;heoVbW0GQR1XS
HAL-01 NH3Zc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\Sfos2UUN3ME2xMlE3QTR|IN88US=> NVnwNoN5W0GQR1XS
IST-MEL1 NYPSZpJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\KeWdxUUN3ME2xMlE4PjV7IN88US=> NGfoPHVUSU6JRWK=
NCI-H719 M1rQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHiwb3dKSzVyPUGuNVc5QThizszN NXu4eoNvW0GQR1XS
EVSA-T MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTPTYxKSzVyPUGuNVgyOTRizszN Mn\yV2FPT0WU
SK-NEP-1 NVrLS49GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO0U3JJUUN3ME2xMlIxOjZ4IN88US=> MnXUV2FPT0WU
OCUB-M M2XqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\HbYtKSzVyPUGuNlE1QDlizszN MXHTRW5ITVJ?
MEG-01 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz0XpFZUUN3ME2xMlIzOTF6IN88US=> M1Pab3NCVkeHUh?=
no-10 NXLGfnpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\CT2Y3UUN3ME2xMlI{OTF{IN88US=> M3n3[XNCVkeHUh?=
MHH-CALL-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwMkS3NlEh|ryP M1jIcXNCVkeHUh?=
SK-N-DZ MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LGZWlEPTB;MT6yOFc4PiEQvF2= NETMdppUSU6JRWK=
SCLC-21H M1u4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG0eYc3UUN3ME2xMlI3PDd6IN88US=> Ml3QV2FPT0WU
CTV-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn0V3VKSzVyPUGuNlc1OjVizszN MX3TRW5ITVJ?
NB1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHrZ5hKSzVyPUGuNlc4OzJizszN MoXhV2FPT0WU
NCI-H64 NV\aUm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLvTWM2OD1zLkK4OFYzKM7:TR?= MXnTRW5ITVJ?
MDA-MB-134-VI MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G3XWlEPTB;MT6yPFU4PyEQvF2= NGm4N|dUSU6JRWK=
LB2241-RCC M3jXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjXUWk{UUN3ME2xMlI5PjZ|IN88US=> NX\sUWJrW0GQR1XS
8-MG-BA Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIftfFlKSzVyPUGuNlg5PjZizszN MUXTRW5ITVJ?
LP-1 NVfw[noxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHiw[WVKSzVyPUGuNlk6PDdizszN M4LHUnNCVkeHUh?=
LS-411N MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LhVmlEPTB;MT6zNFk6QCEQvF2= NYHRZ3NWW0GQR1XS
CAL-148 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnZXHplUUN3ME2xMlMzPTR{IN88US=> MonlV2FPT0WU
NCI-H2171 NUTjSpRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrZbWhKSzVyPUGuN|Q2ODJizszN M2PU[XNCVkeHUh?=
JiyoyeP-2003 NXXr[YRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnDTWM2OD1zLkO1N|kh|ryP M3\n[nNCVkeHUh?=
NCI-H2107 M{LOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe1cVY5UUN3ME2xMlM2QDh|IN88US=> NIL1OFVUSU6JRWK=
BB30-HNC MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPoTXo5UUN3ME2xMlM5QTd6IN88US=> MWrTRW5ITVJ?
K-562 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwM{myNVkh|ryP MmLkV2FPT0WU
PSN1 M4PhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPJcFlKSzVyPUGuOFIzQDdizszN MXfTRW5ITVJ?
HCC2157 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\YXVVvUUN3ME2xMlQzPjlzIN88US=> MnPaV2FPT0WU
SBC-1 NEjqW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmiyTWM2OD1zLkSyO|QyKM7:TR?= NV3oOGVwW0GQR1XS
MC116 NGPL[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzCWpBkUUN3ME2xMlQ{PjF3IN88US=> M1i3PHNCVkeHUh?=
KARPAS-422 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLCTWM2OD1zLkS1N|U5KM7:TR?= Mn7oV2FPT0WU
LB996-RCC M2fsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC0co1PUUN3ME2xMlQ4OTB|IN88US=> MmLwV2FPT0WU
MSTO-211H NF\BdXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHi2enJKSzVyPUGuOFc6QDdizszN NX3icW9wW0GQR1XS
BT-474 NXf1[no4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonzTWM2OD1zLkWxO|Y1KM7:TR?= NUTPPVc5W0GQR1XS
A388 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj4NotKSzVyPUGuOVE6PDVizszN NX\VSnVJW0GQR1XS
SJSA-1 NUfIR4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v4N2lEPTB;MT61NlI3KM7:TR?= NXfaVnBVW0GQR1XS
COLO-829 NE\MW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL3TWM2OD1zLkWzOVY1KM7:TR?= MlS4V2FPT0WU
KM-H2 Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwNU[2O{DPxE1? NFT5dHJUSU6JRWK=
GR-ST M2PCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwNU[4NkDPxE1? NWjYOlVWW0GQR1XS
RPMI-8866 NFr6dZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzofYhKSzVyPUGuOlAyPDRizszN NYLZS3ZSW0GQR1XS
KG-1 NFzJfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1SyXGlEPTB;MT62NVkxOSEQvF2= NVzDXIZyW0GQR1XS
NCI-H82 Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HPUWlEPTB;MT62N|QxPiEQvF2= NFzIT21USU6JRWK=
LB1047-RCC M2jEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHNdWgxUUN3ME2xMlY{PDV7IN88US=> MVrTRW5ITVJ?
KM12 NUX1RlBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzLZodKSzVyPUGuOlQ4KM7:TR?= NYjW[2FqW0GQR1XS
NB5 NIHjUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX6O2kyUUN3ME2xMlY2Pjd5IN88US=> NWj5SmxtW0GQR1XS
HDLM-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwNkiyPFEh|ryP MWHTRW5ITVJ?
KU812 NWm2UYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\2fnpKSzVyPUGuOlk3ODVizszN NGjM[llUSU6JRWK=
DB NFPRbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrLbpBjUUN3ME2xMlcxOzV|IN88US=> NIjpRYZUSU6JRWK=
HD-MY-Z NEDUS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnmT|ZKSzVyPUGuO|UzOzRizszN NGnGco9USU6JRWK=
KURAMOCHI NWWxe|ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LmSmlEPTB;MT63O|IxPyEQvF2= M{TCbHNCVkeHUh?=
ETK-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwN{i4O|kh|ryP MortV2FPT0WU
SK-UT-1 MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwN{mzPFgh|ryP MXvTRW5ITVJ?
HUTU-80 NIizdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPafXFEUUN3ME2xMlc6PTB6IN88US=> NXrLc41tW0GQR1XS
ES7 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\WZolyUUN3ME2xMlgxOzB{IN88US=> NG[zfWlUSU6JRWK=
SW872 NXXp[XlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzlTWM2OD1zLkixN|k2KM7:TR?= M3nNdnNCVkeHUh?=
TK10 NX;qXGNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r4RWlEPTB;MT64N|ExQCEQvF2= NVHrOpRtW0GQR1XS
LB831-BLC NV7GTlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFwOEO1OlMh|ryP M1LKZnNCVkeHUh?=
TE-9 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwOES0NlIh|ryP MVPTRW5ITVJ?
MLMA NHSz[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHwZ29KSzVyPUGuPFgzOzRizszN MWDTRW5ITVJ?
D-542MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;reWlEPTB;MT64PVM4OyEQvF2= NYn1dmlCW0GQR1XS
EW-16 NEC1cIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrYVVFKSzVyPUGuPVI4OiEQvF2= MWDTRW5ITVJ?
LOXIMVI MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFwOUOyPEDPxE1? NHnybFhUSU6JRWK=
GB-1 M1PmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPSTWlvUUN3ME2xMlk{QDZ4IN88US=> M{T3[nNCVkeHUh?=
IST-SL2 MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PWdWlEPTB;Mj6wNFI3OiEQvF2= M4W3SnNCVkeHUh?=
LAN-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT0blNrUUN3ME2yMlAyQTZ4IN88US=> NUTocmk4W0GQR1XS
NCI-H510A NVi5N2tuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLEdXU1UUN3ME2yMlA1PTB{IN88US=> MW\TRW5ITVJ?
NCI-H1092 NXzXRpBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDHTWM2OD1{LkC1NVI1KM7:TR?= MljRV2FPT0WU
HT NW\6dnJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOyfnlSUUN3ME2yMlExPDV2IN88US=> MXXTRW5ITVJ?
RL95-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHi[m1KSzVyPUKuNVE1QDJizszN NIPiTopUSU6JRWK=
NCI-H1355 Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfiRWFDUUN3ME2yMlEyPzl{IN88US=> M1\HSXNCVkeHUh?=
NCI-H720 NWTuRZV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJwMU[4O|Mh|ryP MoLHV2FPT0WU
NCI-H1522 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPhXXRKSzVyPUKuNlE4OjNizszN NHHJd|NUSU6JRWK=
LB373-MEL-D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJwMk[5NFIh|ryP NF;vNZlUSU6JRWK=
DG-75 NHnDTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHmN4tKSzVyPUKuNlcyPDhizszN NF[0RpJUSU6JRWK=
ML-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFyxfGhKSzVyPUKuN|I5PTVizszN M364eXNCVkeHUh?=
SF126 MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n2VGlEPTB;Mj6zN|A6PCEQvF2= Mn3uV2FPT0WU
MPP-89 M1jLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJwM{OxOFUh|ryP MVfTRW5ITVJ?
NCI-H345 M1jqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYroRm43UUN3ME2yMlM{Ojd5IN88US=> MWDTRW5ITVJ?
LS-123 M33VOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi5fphXUUN3ME2yMlM1QTN4IN88US=> NWGxeWJKW0GQR1XS
NB10 NUHsRZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwNEGwPVIh|ryP MXXTRW5ITVJ?
CGTH-W-1 M17qb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjpclZLUUN3ME2yMlQzOjZ5IN88US=> NUjHXnB7W0GQR1XS
CP66-MEL MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJwNEe3O{DPxE1? NHLsOVVUSU6JRWK=
L-428 NUW0N5p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjCTWM2OD1{LkS4OVIyKM7:TR?= Ml7vV2FPT0WU
DMS-79 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWiyNFRVUUN3ME2yMlU1OTB|IN88US=> NV[5UpV1W0GQR1XS
NCI-H1882 NXXSPFlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJwNke1OlIh|ryP M3nLXXNCVkeHUh?=
KGN NXH1c2VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\LW|F4UUN3ME2yMlc3QDd4IN88US=> NWTOSJo{W0GQR1XS
EW-1 NH:0WIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwN{ewPFMh|ryP MVHTRW5ITVJ?
U-266 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTOTWM2OD1{Lki0PFI{KM7:TR?= NX25TnJ3W0GQR1XS
COLO-320-HSR M2SyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;wVWlEPTB;Mj64OVY1OSEQvF2= M2DE[nNCVkeHUh?=
KMOE-2 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXwTWM2OD1{Lki3O|EyKM7:TR?= MXvTRW5ITVJ?
BB49-HNC M13vXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\vTWM2OD1{LkmyOFgh|ryP MXfTRW5ITVJ?
GI-1 NF7BNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjJ[I5KSzVyPUKuPVI6PTdizszN M{HlOnNCVkeHUh?=
NCI-H1304 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnlT5ZKSzVyPUOuNFA2OTFizszN NH6wW5BUSU6JRWK=
NCI-H2227 NXfMe3NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXYS2VKSzVyPUOuNFIxPzlizszN NGPCZYdUSU6JRWK=
U-87-MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfTPW5KSzVyPUOuNFM2OTNizszN M{HER3NCVkeHUh?=
NCI-H747 NUXHbmk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\nTHhKSzVyPUOuNFUzODZizszN M2\wdnNCVkeHUh?=
CTB-1 M17sSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy0WnB7UUN3ME2zMlA2Ozd4IN88US=> MWrTRW5ITVJ?
RPMI-8226 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICyZmZKSzVyPUOuNVQ{PzhizszN NXTNSWlEW0GQR1XS
NCI-H2141 M3r0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\MS2lEPTB;Mz6xOlU3PiEQvF2= NEXZRVRUSU6JRWK=
IST-MES1 M1m5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTNwMUiyO|kh|ryP NIHmXGtUSU6JRWK=
TE-5 M4XRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LZPWlEPTB;Mz6yNVM1OiEQvF2= MnfUV2FPT0WU
UACC-257 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNwNEO2OVkh|ryP MWnTRW5ITVJ?
SK-N-FI MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj2TWM2OD1|LkS1NlI4KM7:TR?= NWDZNphVW0GQR1XS
MFH-ino MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrEN41KSzVyPUOuOFY2QDlizszN M1fLb3NCVkeHUh?=
SF268 MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HlfGlEPTB;Mz60PFE4PCEQvF2= MnW4V2FPT0WU
TE-12 NWTjWIVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\5TWM2OD1|LkWxOlk6KM7:TR?= Mn24V2FPT0WU
NB6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnI[IJKSzVyPUOuOVU2PjNizszN MVLTRW5ITVJ?
DJM-1 NFKxVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LGeGlEPTB;Mz61PVg6QSEQvF2= NFfUc45USU6JRWK=
MZ1-PC M33HNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzJSopIUUN3ME2zMlYyPjJ2IN88US=> MlPzV2FPT0WU
OCI-AML2 NF72R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\aTWM2OD1|Lk[yOlcyKM7:TR?= NWnPZY95W0GQR1XS
NCI-H1155 M2XqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfTdWE3UUN3ME2zMlcxQTR5IN88US=> MV\TRW5ITVJ?
RKO MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTNwN{exPFkh|ryP NVS3cpA2W0GQR1XS
ECC4 NXH3V5liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MluyTWM2OD1|Lkm3NVk2KM7:TR?= NYD2[HJjW0GQR1XS
BB65-RCC Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTNwOUe1OFch|ryP M1i2UHNCVkeHUh?=
EB-3 NUf1cIxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrlSIZKSzVyPUOuPVk3OzNizszN NHnVdGtUSU6JRWK=
SHP-77 NFvBW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLiR5d[UUN3ME20MlAxPTJ2IN88US=> M1rUXnNCVkeHUh?=
NCI-H2196 NF62UGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf0TWM2OD12LkC1OlI2KM7:TR?= NEPGUVdUSU6JRWK=
GI-ME-N MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHjXVVKSzVyPUSuNFY{QTlizszN MUjTRW5ITVJ?
MN-60 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTRwMUC4O{DPxE1? M3\KUXNCVkeHUh?=
NCI-H1694 NXPWc2s5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\je|dKSzVyPUSuNVM1ODVizszN MnXEV2FPT0WU
LU-65 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrETWM2OD12LkG1N|MzKM7:TR?= NX\0XFhbW0GQR1XS
NCI-H1436 NGTiRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PJfmlEPTB;ND6xPFM{OyEQvF2= MXLTRW5ITVJ?
KINGS-1 NYO3PIZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnETWM2OD12LkOxOFMzKM7:TR?= Ml\4V2FPT0WU
GT3TKB NIrCVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W5RWlEPTB;ND6zN|I3QCEQvF2= MWnTRW5ITVJ?
Becker M1PEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq3TWM2OD12LkO3N|EzKM7:TR?= NFLGOFZUSU6JRWK=
HCC1187 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT6UWpSUUN3ME20Mlg6PjV5IN88US=> NHTOUFBUSU6JRWK=
D-502MG NFe4T29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Dl[WlEPTB;NT6wNFQyPiEQvF2= MULTRW5ITVJ?
VA-ES-BJ MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrNTWM2OD13LkGzO|c5KM7:TR?= M1zaXXNCVkeHUh?=
NB7 NITJeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTVwMUSxNVIh|ryP NXPTWFFiW0GQR1XS
SW962 NYG0Omk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmyPINKSzVyPUWuN|g5OTRizszN M3m4XnNCVkeHUh?=
no-11 M3j0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXjZ5ZjUUN3ME21Mlc3OzR|IN88US=> NYDQVVN{W0GQR1XS
KNS-81-FD MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjZS3JKSzVyPUWuPVA3QTRizszN M1LnN3NCVkeHUh?=
COLO-684 NHPDe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnOTWM2OD13Lkm5OFk1KM7:TR?= M{noNHNCVkeHUh?=
D-263MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKzTWM2OD14LkC4PFk2KM7:TR?= Ml3wV2FPT0WU
EW-24 MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZwMki1NUDPxE1? NV;qc257W0GQR1XS
TE-10 M4LqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnMeJpKSzVyPU[uOFI3OjNizszN NH;xTHNUSU6JRWK=
EKVX Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q5U2lEPTB;Nj60OlMzOSEQvF2= MlTpV2FPT0WU
NCI-H1648 NITSbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPXTWM2OD14Lk[3OVU4KM7:TR?= NVrU[XZpW0GQR1XS
LB771-HNC NHvNVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nMNmlEPTB;Nj65NlMxOSEQvF2= M{n0Z3NCVkeHUh?=
SK-MEL-1 M2LHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRThwMUOxOlYh|ryP M2nxU3NCVkeHUh?=
COLO-668 M3:xcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHsWIRwUUN3ME24MlI4Pzh4IN88US=> NYfBU5VjW0GQR1XS
EW-12 NWPp[m1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XEO2lEPTB;OD60NFgxOyEQvF2= NEfMdopUSU6JRWK=
A253 NX7RNYg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHhdFJvUUN3ME24Mlg1PjZzIN88US=> MnzVV2FPT0WU
NCI-H2126 M3fVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TBW2lEPTB;OD64PVMyQSEQvF2= NXrOS4NFW0GQR1XS
Calu-6 NFuwNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC4TWM2OD16Lkm5NFQzKM7:TR?= MXPTRW5ITVJ?
NCI-H23 M1f6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTlwMUe3OFYh|ryP MX;TRW5ITVJ?
WSU-NHL NH7sXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTlwN{e0O|gh|ryP MorIV2FPT0WU
MMAC-SF MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\pc2lEPTB;OT65O|kxPCEQvF2= MU\TRW5ITVJ?
SK-LMS-1 NXy4WGFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFyLkK4N|Qh|ryP NEDoeZhUSU6JRWK=
GCIY MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X2dmlEPTB;MUCuOVkzPCEQvF2= M4rLOHNCVkeHUh?=
TE-15 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;VTWM2OD1zMT62NFA1KM7:TR?= M{PlOXNCVkeHUh?=
EoL-1-cell NEfDb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfYfmhKSzVyPUGxMlc3QDJizszN NVXReGdOW0GQR1XS
NCI-H2081 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ifXVFUUN3ME2xNU44Pzh4IN88US=> MVPTRW5ITVJ?
EW-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLZR2pKSzVyPUGyMlI1PjNizszN NIPhXGpUSU6JRWK=
CAS-1 M4SxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfiTWM2OD1zMj6zOlMyKM7:TR?= NEnmcItUSU6JRWK=
C2BBe1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF{Lk[xN|Eh|ryP NEG2XFlUSU6JRWK=
D-247MG MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF{Lke5OVIh|ryP MnLnV2FPT0WU
NCI-SNU-5 NF;5fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF{LkiwNVMh|ryP MX3TRW5ITVJ?
LS-1034 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LZO2lEPTB;MUSuN|k4PSEQvF2= MmPwV2FPT0WU
EW-18 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e1[mlEPTB;MUSuOFQ5KM7:TR?= MXHTRW5ITVJ?
Raji MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF2LkWwOFkh|ryP M3TsWHNCVkeHUh?=
D-283MED NUjSeWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrJeJVKSzVyPUG0MlYzPzFizszN M{e2WHNCVkeHUh?=
MZ2-MEL M2TMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF2Lkm2PVYh|ryP NGHNcVBUSU6JRWK=
NCI-SNU-16 NF\UWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF3LkS2N|Mh|ryP M3vjfHNCVkeHUh?=
P30-OHK M1\sVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe3bIFNUUN3ME2xO{44QDNzIN88US=> Mn7ZV2FPT0WU
RXF393 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLXTWM2OD1zOT6wNVg3KM7:TR?= Mmj2V2FPT0WU
NCI-H1395 M3f2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;1VGw4UUN3ME2yNE43PzB|IN88US=> MmTwV2FPT0WU
U-698-M NXTYRmRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPJTWM2OD1{MD63NFc2KM7:TR?= NYL0Tmh4W0GQR1XS
NCI-SNU-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;GTGlEPTB;MkCuO|IzOyEQvF2= M3:wSXNCVkeHUh?=
SW684 M3i5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16ybmlEPTB;MkGuNVcyPiEQvF2= NH3rVYFUSU6JRWK=
NCI-H716 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHpTWM2OD1{MT6zNVU1KM7:TR?= M3jYV3NCVkeHUh?=
JVM-2 NHy4OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJzLkSxN|Mh|ryP NX\JPWFYW0GQR1XS
NCI-H1581 NUnpbZB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD1TWM2OD1{Mj60NVQ5KM7:TR?= NFPBNZRUSU6JRWK=
CA46 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXX[5VKSzVyPUOxMlY6OzZizszN NYjsNo1FW0GQR1XS
SNB75 MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37sSWlEPTB;M{OuOlUxOyEQvF2= MWDTRW5ITVJ?
KNS-42 NEPtU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLofIpPUUN3ME2zOU46PjJ2IN88US=> NX6wN4lnW0GQR1XS
TUR MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PScGlEPTB;M{[uNFUzOSEQvF2= Mn72V2FPT0WU
REH MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzHflJKSzVyPUO3MlgzOTFizszN M2LMbHNCVkeHUh?=
EW-22 NH6zW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPXbldsUUN3ME20Nk4zQDh3IN88US=> NWDoZZFFW0GQR1XS
NCI-H446 MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f0OWlEPTB;NEKuO|g2OyEQvF2= MVzTRW5ITVJ?
ES3 NXfhOZloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnic2EzUUN3ME20N{4yOzN7IN88US=> MXfTRW5ITVJ?
EW-11 NVzvN5lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTR2LkiyNVgh|ryP MYXTRW5ITVJ?
RH-1 NEnXc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf3TWM2OD12Nz61PFEzKM7:TR?= MmmwV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

- Collapse

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

- Collapse
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275
Smiles NC1=CC=CC=C1NC(=O)C2=CC=C(CNC(=O)OCC3=CN=CC=C3)C=C2

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1
NCT03192111 Completed Drug: Entinostat Renal Impairment|Healthy Volunteer Syndax Pharmaceuticals July 27 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID